TaiMed Biologics

Advancing CD4-targeted biologics
for long-acting HIV treatment and beyond

TaiMed is a commercial-stage biologics company building on
nearly two decades of CD4-targeted science to advance
differentiated antibody therapies.
Our lead clinical program, TMB-365/380,
is being developed as a long-acting HIV maintenance
regimen designed around durable viral suppression,
broader applicability, and greater clinical simplicity
in real-world care.

TaiMed Biologics
Advancing CD4-targeted biologics for
long-acting HIV treatment and beyond

TaiMed is a commercial-stage biologics company building
on nearly two decades of CD4-targeted science to advance differentiated antibody therapies.
Our lead clinical program, TMB-365/380, is being developed as a long-acting HIV maintenance regimen
designed around durable viral suppression, broader applicability,
and greater clinical simplicity in real-world care.

TaiMed Biologics
Advancing CD4-targeted biologics for
long-acting HIV treatment and beyond

TaiMed is a commercial-stage biologics company building
on nearly two decades of CD4-targeted science to advance differentiated antibody therapies.
Our lead clinical program, TMB-365/380, is being developed as a long-acting HIV maintenance regimen
designed around durable viral suppression, broader applicability,
and greater clinical simplicity in real-world care.

TaiMed Biologics
Advancing CD4-targeted biologics for
long-acting HIV treatment and beyond

TaiMed is a commercial-stage biologics company building
on nearly two decades of CD4-targeted science to advance differentiated antibody therapies.
Our lead clinical program, TMB-365/380, is being developed as a long-acting HIV maintenance regimen
designed around durable viral suppression, broader applicability,
and greater clinical simplicity in real-world care.

View Our Pipeline

A validated foundation. A next generation of possibilities

CD4 is the scientific foundation connecting TaiMed's portfolio. Our experience spans the first FDA-approved monoclonal antibody for HIV treatment, a next-generation long-acting dual-antibody program in Phase 2b, and preclinical CD4-directed research in HIV cure and other immune-directed applications.

Products

Trogarzo®

Clinical and commercial foundation

TMB-365/380

Lead clinical program

CD4-ADC

Platform extension

Trogarzo established the clinical and regulatory foundation for TaiMed's CD4-targeted antibody approach and demonstrated the company's ability to advance a novel biologic through approval and commercialization.

An investigational long-acting dual-antibody maintenance regimen combining host-cell CD4 targeting with a virus-targeting broadly neutralizing antibody. Phase 2b enrollment is complete.

Preclinical research applying TaiMed's CD4-targeting expertise to targeted payload delivery in HIV cure research and other immune-directed areas.

TMB-365/380
Lead clinical program

An investigational long-acting dual-antibody maintenance regimen combining host-cell CD4 targeting with a virus-targeting broadly neutralizing antibody. Phase 2b enrollment is complete.

ABOUT

Broadening the potential of long-acting HIV maintenance

TMB-365/380 is being developed as a complete, antibody-only maintenance regimen for virologically suppressed adults. Its complementary host-and-virus targeting strategy is designed to support durable disease control while reducing small-molecule backbone complexity and exploring the potential for broader real-world applicability.

PROOF POINTS

We are doing a couple of things you might be interested in

94%
Maintained HIV-1 RNA below 50 copies/mL through Week 24 in Phase 2a

0
Virologic failures among Phase 2a study completers

Q2M
Every-two-month dosing evaluated in Phase 2a and Phase 2b

PHASE 2B
Enrollment completed; interim analysis expected by year-end 2026

Long-acting HIV is not one-size-fits-all

Fewer doses can matter, but meaningful innovation in HIV maintenance therapy depends on more than dosing interval alone. As people with HIV live longer and care becomes more complex, the field must also consider efficacy, safety, treatment eligibility, polypharmacy and drug-drug interactions, resistance, clinical flexibility, and fit with ongoing care. TaiMed is developing antibody-based approaches with these realities in mind.

Applicability
How many patients can realistically access and remain on a treatment matters as much as how often it is dosed.

Treatment complexity
Comorbidities and polypharmacy can add significant complexity to lifelong HIV management, increasing the importance of regimen design and DDI considerations.

Clinical flexibility
The future of long-acting care is likely to include multiple dosing and delivery options tailored to different patient needs rather than a single universal interval.

Biologics development experience that extends beyond our own pipeline

TaiMed's biologics development and manufacturing capabilities support both our internal programs and selected external partners. Our CDMO team provides integrated services across process development, analytical development, formulation, cGMP manufacturing, and regulatory support.

Process Development

Formulation Development

cGMP Manufacturing

Analysis and Analytical Method Development

Regulatory Affairs

Explore CDMO Services

Built through global collaboration

TaiMed's progress has been shaped by collaborations spanning leading HIV research institutions, development and manufacturing organizations, and commercialization partners. We continue to pursue relationships that can accelerate the reach and impact of differentiated biologics.

合作夥伴

中裕新藥與相關生技醫療機構合作，持續研發促進人民福祉之技術

Aaron Diamond AIDS Research Center

Theratechnologie

The Rockefeller University

Samsung Biologics

National Institutes of Health